Chemical Structure (Tiglutik 01)
Tiglutik Liquid
Product Images NDC 70726-0303
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Tiglutik (NDC 70726-0303). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Edw Pharma, Inc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Figure 1 (Tiglutik 02)
This is a description of the Kaplan-Meier Survival Curves for Riluzole and Placebo. The survival probability at various time points is presented, along with the number of participants in each group (77 for Riluzole and 78 for Placebo). No additional context or information is available.*
Figure 2 (Tiglutik 03)
This is a description of a graph showing the Kaplan-Meier survival curves for a placebo group and a group taking Riluzole 50mg twice a day. The survival probability is being analyzed. No further information is available.*
Principal Display Panel (300 mL Bottle Carton)
This is a drug called Tiglutik with the active ingredient Riluzole. It is an oral suspension containing 50mg of Riluzole per 10mL (5mg/ml) supplied with syringes for oral administration. The product comes in two bottles, each containing 300mL, and includes two 10mL oral syringes and two syringe bottle adapters. The liquid suspension is slightly brown opaque and should be shaken gently before use. It is important to read the enclosed Prescribing Information before use. The total amount of the product is 600mL, which comes in two bottles not to be dispensed separately. Proper disposal is recommended, and it should be kept out of reach of children.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
